Saranas
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2450 Holcombe Blvd Ste X, Houston, Texas...Phone Number
(713) 357-1049Website
www.saranas.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Saranas
Saranas is a privately held Houston-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company's patented Early Bird Bleed Monitoring System for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs.Explore more
Saranas Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Saranas your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Saranas had a recent Job posting/layoffs
Product Launch: Get notified when Saranas launches new products
Funding: Get notified immidiatlly once Saranas has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Saranas recently announced quarterly report
Check out if Saranas is spiking on competitors!
Check if Saranas has recently received funding, and reach out quickly before it becomes old news!
Saranas, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Saranas
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Saranas
Find more new buyers
Compare Similar Companies to Saranas
Compare insights from companies similar to Saranas, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Saranas is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Saranas is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Saranas.
Saranas financials insights
Gather financial insights about Saranas, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Angel/Seed
$1.2M
2015
Unspecified
$2.4M
2016
Series A
$3.5M
Private Equity
$1.4M
2017
Series B
$4M
2018
Series C
$2.8M
2021
Series B
$12.8M
Saranas Tech Stack
A closer look at the technologies used by Saranas
See more technologies
Most Recent Scoops
New Hire
Executive Move
Mike MacKinnon has assumed the role of Chief Executive Officer. Previously, MacKinnon served as Partner & President of Madison Ventures.
New Hire
Executive Move
Frank Natale has been named Vice President, Sales. Previously, Natale served as Director, Area Business (West) at Itamar Medical.
Funding
Funding
Funding
Saranas News & Media
Saranas Successfully Completes Enrollment of Clinical Trial Assessing the Utility of Early Bleed Detection in Patients Undergoing Mechanical Circulatory Support
HOUSTON--(BUSINESS WIRE)--Saranas, Inc. announced today that it has completed enrollment in SAFE-MCS, a multi-center, single arm, open-label clinical trial evaluating the safety of complex high-risk percutaneous coronary intervention (PCI) using mechanical circulatory support (MCS) and surveillance with the Early Bird® Bleed Monitoring System. The Early Bird Bleed Monitoring System is the first and only FDA-approved bleed detection system. It was launched in 2019 following a De Novo classificatSaranas Reaches Midpoint for Enrollment in Clinical Trial Assessing the Utility of Early Bleed Detection in Patients Undergoing Mechanical Circulatory Support
HOUSTON--(BUSINESS WIRE)--Saranas, Inc. announced today that it has reached the midpoint for enrollment in SAFE-MCS, a multi-center, single arm, open-label clinical trial evaluating the safety of complex high-risk percutaneous coronary intervention (PCI) using mechanical circulatory support (MCS) and surveillance with the Early Bird® Bleed Monitoring System. The Early Bird Bleed Monitoring System is the first and only FDA-approved bleed detection system. It was launched in 2019 following a De NSaranas Appoints Mike MacKinnon as CEO
HOUSTON--(BUSINESS WIRE)--Saranas® Inc., a medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications, today announced the hiring of seasoned medtech executive, Mike MacKinnon, as Chief Executive Officer. He joins the company to accelerate commercialization of its Early Bird Bleed Monitoring System – the first and only system FDA-approved bleed detection system for endovascular procedures. It is designed to detect bleedSaranas Announces Over 1,200 Patients Treated with the Early Bird® Bleed Monitoring System
HOUSTON--(BUSINESS WIRE)--Saranas, Inc. announced today that over 1,200 patients have been treated with the Early Bird® Bleed Monitoring System, the first and only FDA-approved bleed detection system. The Early Bird was launched in 2019 following a De Novo classification by the U.S. Food and Drug Administration. The device monitors and detects endovascular bleed complications through a novel application of bioimpedance sensors. “Compared to the current paradigm of waiting for symptoms, which co
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Saranas
Sign Up For FreeTo access detailed company insights
Saranas is a privately held Houston-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company's patented Early Bird Bleed Monitoring System for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding compl... Read More
